1171 related articles for article (PubMed ID: 28245875)
21. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Gettinger SN; Horn L; Gandhi L; Spigel DR; Antonia SJ; Rizvi NA; Powderly JD; Heist RS; Carvajal RD; Jackman DM; Sequist LV; Smith DC; Leming P; Carbone DP; Pinder-Schenck MC; Topalian SL; Hodi FS; Sosman JA; Sznol M; McDermott DF; Pardoll DM; Sankar V; Ahlers CM; Salvati M; Wigginton JM; Hellmann MD; Kollia GD; Gupta AK; Brahmer JR
J Clin Oncol; 2015 Jun; 33(18):2004-12. PubMed ID: 25897158
[TBL] [Abstract][Full Text] [Related]
22. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
[No Abstract] [Full Text] [Related]
24. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
Rounds A; Kolesar J
Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
[TBL] [Abstract][Full Text] [Related]
26. Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer.
Dasanu CA; Lippman SM; Plaxe SC
J Oncol Pharm Pract; 2017 Dec; 23(8):638-640. PubMed ID: 27824586
[TBL] [Abstract][Full Text] [Related]
27. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
28. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
[TBL] [Abstract][Full Text] [Related]
29. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
30. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract][Full Text] [Related]
31. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I
Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261
[TBL] [Abstract][Full Text] [Related]
32. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
[TBL] [Abstract][Full Text] [Related]
33. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
34. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
35. Effect and biomarker of Nivolumab for non-small-cell lung cancer.
Wang L; Zhao D; Qin K; Rehman FU; Zhang X
Biomed Pharmacother; 2019 Sep; 117():109199. PubMed ID: 31387181
[TBL] [Abstract][Full Text] [Related]
36. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Nishino M; Ramaiya NH; Awad MM; Sholl LM; Maattala JA; Taibi M; Hatabu H; Ott PA; Armand PF; Hodi FS
Clin Cancer Res; 2016 Dec; 22(24):6051-6060. PubMed ID: 27535979
[TBL] [Abstract][Full Text] [Related]
37. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
38. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
40. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
